Research programme: erythropoietin controlled release - Flamel Technologies
Latest Information Update: 10 Jan 2008
At a glance
- Originator Flamel Technologies
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 02 Feb 2004 Preclinical trials in Anaemia in France (unspecified route)